Vanguard® Rapid Resp Becomes First and Only Vaccine Licensed to Provide Dogs with One-Year Duration of Immunity from Three Canine Infectious Respiratory Diseases
Vaccine helps protect against Bordetella bronchiseptica, canine adenovirus
type 2 and canine parainfluenza virus infections
PARSIPPANY, N.J. — December 18, 2017 — Zoetis today announced that the United States Department of Agriculture (USDA) has granted the Vanguard® Rapid Resp intranasal vaccine line one-year duration of immunity (DOI) claims for the Bordetella bronchiseptica (Bb), canine adenovirus type 2 (CAV-2) and canine parainfluenza virus (CPiV) fractions. Vanguard Rapid Resp is the first and only intranasal vaccine line in the United States that has been demonstrated to provide one year of protection against three important Canine Infectious Respiratory Diseases (CIRD). Additionally, the line is the broadest among 0.5 mL intranasal vaccines used in dogs in the United States.
“The demonstration of a one-year duration of immunity for all three antigens in Vanguard Rapid Resp represents an important step in the protection of dogs from CIRD. This new DOI confirms the efficacy of a single product that provides both rapid and durable protection against these important antigens in the CIRD complex,” said Stephan Carey, DVM, PhD, DACVIM, assistant professor of Small Animal Clinical Sciences at Michigan State University College of Veterinary Medicine.* “This extended DOI is essential in reducing morbidity and mortality from infectious respiratory disease among dogs in social or commingled environments such as boarding facilities and shelters.”
Infectious respiratory disease in dogs can be caused by many different pathogens, both bacterial and viral. In most instances, the clinical signs will be identical regardless of the infecting pathogen. Co-infections can also occur, leading to more severe symptoms, which makes identifying the proper treatment difficult.
“I am proud of the innovative science which has enabled Zoetis to gain 12-month protection claims for Bordetella bronchiseptica, canine adenovirus 2 (CAV-2) and canine parainfluenza virus (CPiV) fractions of Vanguard Rapid Resp vaccines,” said Annette Litster, BVSc, PhD, FANZCVS, MMed Sci, senior veterinary specialist, Veterinary Specialty Operations Team at Zoetis. “This demonstrates our determination to provide veterinarians with ever better solutions for their clients and canine patients in their care. A 12-month duration of immunity across all three antigens gives us even greater confidence in the protection provided by Vanguard Rapid Resp to help prevent these common and widespread infections.”
Vanguard Rapid Resp is available in three antigenic combinations (Bb + CPiV + CAV-2; Bb + CPiV; Bb only), and all of these choices can be administered with a syringe or a syringe-free applicator.
To learn more about Vanguard Rapid Resp, visit VanguardRapidResp.com.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
*Dr. Stephan Carey is a consultant to Zoetis.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States